ADDvise Group AB has today entered into a share purchase agreement with the owners of Seebreath AB (“Seebreath”) regarding the acquisition of all the outstanding shares of Seebreath. The acquisition is in line with the letter of intent communicated via a press release dated February 28, 2022. Closing of the acquisition takes place today. Seebreath’s…
Read moreADDvise Group is an expanding group that offers total solutions in the form of products and services to healthcare and research facilities through its subsidiaries within the business units Lab and Healthcare.
Expanding and developing ADDvise and our subsidiaries today feels more important than ever. We strive to extend, improve, and save people’s lives by developing and providing products and services for healthcare and research segments.
ADDvise Group AB has today entered into a share purchase agreement with the owners of Seebreath AB (“Seebreath”) regarding the acquisition of all the outstanding shares of Seebreath. The acquisition is in line with the letter of intent communicated via a press release dated February 28, 2022. Closing of the acquisition takes place today. Seebreath’s…
Read moreADDvise Group AB (publ), reg. no. 556363–2115, has held its annual general meeting on May 6, 2022 at 10.00 a.m. at Grev Turegatan 30 in Stockholm. At the meeting, the following resolutions were, amongst others, adopted.
Read moreJanuary-March 2022 Net revenue for the period was SEK 162.4 million (87.7), an increase of 85.1 %. Organic growth was 4.2 %. Adjusted EBITDA for the period was SEK 21.3 million (8.0) EBITDA for the period was SEK 21.2 million (8.9) Adjusted profit/loss for the period was SEK 5.8 million (1.6) Basic earnings per share…
Read moreADDvise Group AB has today entered into a share purchase agreement with the owners of Surplus Diabetics, Inc. (“Surplus Diabetics”) regarding the acquisition of all the outstanding shares of Surplus Diabetics in accordance with the letter of intent communicated via a press release dated January 17, 2022. Closing of the acquisition takes place today. Surplus…
Read moreADDvise Interim report Q4 2021 with comments from CEO Rikard Akhtarzand. The Group’s position at the end of 2021 was strong. Organic growth in Q4 amounted to 12.8 percent, and adjusted EBITDA increased by 51 percent in the same quarter.
Net revenue in the fourth quarter amounted to SEK 155.0 million, an increase of 60.1 percent compared to the fourth quarter of 2020, when net revenue amounted to SEK 96.8 million. Net revenue increased organically by 12.8 percent. During the fourth quarter, the Group had no tangible revenue attributable to Covid-19.
For more presentations please visit our YouTube channel.
Together we become stronger describes ADDvise leadership strategy. They work guiding and supportive. We have gained access to support functions we did not have in the business before. This has enabled us to easily develop the business and streamline many of our processes and working methods, Jonny Knekthage, CEO Tillquist.
ADDvise delivers equipment and services to healthcare and research units worldwide. The global market for medical technology is growing and is expected to continue to grow in the upcoming years.
ADDvise Group’s two business units Lab and Healthcare are part of the organizational facilitation of the stated acquisition strategy. Together, the business areas create a complete offer for our customers.
Here you will find financial information so that you as a shareholder, analyst or investor can be up to date. Financial reports, press releases and other company information.
Subscribe to our press releases and receive the information directly in the email.
